All In Biotech

Drug Trial Radar · NCT05411861

Post-Operative Pain and Opioid Reduction Trial After Bunionectomy

Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate Safety, Efficacy, and PK of CPL-01 in Post-Op Pain After Unilateral Distal First Metatarsal Bunionectomy + Osteotomy

Last checked: Nov 19, 2026Latest source record: Jan 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Jun 14, 2022

Primary completion

Sep 26, 2022

Study completion Nov 7, 2022

Sponsor

Lead sponsor
Cali Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Jun 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing bunionectomy.

Conditions

  • Hallux Valgus and Bunion

Interventions

  • Analgesic Non NarcoticDrug

    Injection of protocol-specified volume of local analgesic

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC72Time frame: 72 hours post-operative

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Research Center

    Phoenix, Arizona

  • Trovare Clinical Research

    Bakersfield, California

  • Jean Brown Research

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.